MedTrace Logo

Event-related Potentials in Management of Children With Attention-deficit/Hyperactivity Disorder

NCT01130467 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2010-08-10

No results posted yet for this study

Summary

The investigators try to objectively and scientifically explore various brain function impairments in ADHD children by electrophysiologic tests, with and without medication.

Conditions

  • Attention Deficit Disorders With Hyperactivity
  • Attention Deficit Disorder
  • Hyperkinetic Syndrome

Interventions

DRUG

methylphenidate

IR-MPH were started on a dose of 5 mg tid po, and this was increased to 10 mg tid and then to 15 mg tid as necessary. OROS-MPH was started on a dose of 18 mg qd, and this was increased to 36 mg qd and then to 54 mg qd as necessary.

DRUG

Atomoxetine

Atomexetine was started (weight of 70 kg or less) 0.5 mg/kg/day orally and increased after a minimum of 3 days to a target dose of 1.2 mg/kg/day. The maximum dosage is 1.4 mg/kg/day or 100 mg/day (whichever is less).

BEHAVIORAL

behavioral modification

Parenting and teaching skill education

Sponsors & Collaborators

  • Academia Sinica, Taiwan

    collaborator OTHER

  • National Taiwan University Hospital

    collaborator OTHER

  • Far Eastern Memorial Hospital

    lead OTHER

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2011-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01130467 on ClinicalTrials.gov